Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.40 |
| ▸ | WNT1 | P04628 | 15/20 | 0.40 |
| ▸ | GSK3B | P49841 | 15/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776210 | 0.91 | BRAF (0.42) | BRAF | |
| SCHEMBL16776016 | 0.87 | WNT3A (0.40) | ABL1MAPK1 | |
| SCHEMBL16776298 | 0.86 | RHOA (0.39) | DYRK1AWNT1GSK3BBRAF | |
| SCHEMBL16776411 | 0.86 | DYRK1A (0.38) | DYRK1AWNT1GSK3BBRAF | |
| SCHEMBL16776013 | 0.84 | FGFR4 (0.44) | MAPK1 | |
| SCHEMBL19365697 | 0.83 | DYRK1A (0.40) | DYRK1AWNT1GSK3B | |
| SCHEMBL16776024 | 0.82 | IMPDH2 (0.46) | BRAF | |
| SCHEMBL16776229 | 0.81 | CYP11B2 (0.37) | ABL1MAPK1 | |
| SCHEMBL16776226 | 0.81 | HTR2C (0.45) | ABL1 | |
| SCHEMBL16776227 | 0.80 | FGFR4 (0.37) | ABL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DYRK1A 2623/4885WNT1 3363/4885GSK3B 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.